REGENXBIO Inc. (RGNX)
Largest Insider Buys in Sector
RGNX Stock Price History Chart
RGNX Stock Performance
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is …
Insider Activity of REGENXBIO Inc.
Over the last 12 months, insiders at REGENXBIO Inc. have bought $0 and sold $3.63M worth of REGENXBIO Inc. stock.
On average, over the past 5 years, insiders at REGENXBIO Inc. have bought $0 and sold $6.28M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 175,000 shares for transaction amount of $3.85M was made by Flynn James E (10 percent owner) on 2015‑09‑22.
List of Insider Buy and Sell Transactions, REGENXBIO Inc.
| 2024-10-01 | Sale | director | 10,000 0.0191% | $10.11 | $101,052 | -6.17% | ||
| 2024-09-03 | Sale | director | 10,000 0.0206% | $11.56 | $115,588 | -12.52% | ||
| 2024-08-01 | Sale | Chief Executive Officer | 100 0.0002% | $15.00 | $1,500 | -21.19% | ||
| 2024-08-01 | Sale | director | 10,100 0.0208% | $13.51 | $136,454 | -21.19% | ||
| 2024-07-29 | Sale | Chief Executive Officer | 9,648 0.0205% | $15.04 | $145,106 | -26.90% | ||
| 2024-07-29 | Sale | director | 11,000 0.0234% | $15.04 | $165,495 | -26.90% | ||
| 2024-07-25 | Sale | director | 15,369 0.0303% | $13.96 | $214,501 | -26.34% | ||
| 2024-07-24 | Sale | director | 12,221 0.0251% | $13.78 | $168,433 | 0.00% | ||
| 2024-07-17 | Sale | director | 2,210 0.0047% | $13.77 | $30,440 | -19.05% | ||
| 2024-07-16 | Sale | director | 200 0.0005% | $13.76 | $2,752 | -20.54% | ||
| 2024-07-01 | Sale | director | 10,000 0.0199% | $11.27 | $112,691 | 0.00% | ||
| 2024-05-14 | Sale | President and CEO | 15,000 0.0305% | $15.81 | $237,222 | -26.06% | ||
| 2024-04-15 | Sale | President and CEO | 15,000 0.0309% | $18.19 | $272,871 | -33.19% | ||
| 2024-03-14 | Sale | President and CEO | 15,000 0.03% | $21.86 | $327,942 | -42.77% | ||
| 2024-03-05 | Sale | Chief Medical Officer | 12,878 0.0328% | $28.36 | $365,220 | -48.48% | ||
| 2024-02-14 | Sale | President and CEO | 15,000 0.0329% | $16.76 | $251,349 | -22.60% | ||
| 2024-01-16 | Sale | President and CEO | 45,000 0.1017% | $15.18 | $682,992 | -14.11% | ||
| 2024-01-03 | Sale | Chief Medical Officer | 17,237 0.0398% | $17.39 | $299,789 | -21.07% | ||
| 2023-12-19 | Sale | President and CEO | 45,000 0.1027% | $19.68 | $885,825 | -29.60% | ||
| 2023-01-03 | Sale | Chief Medical Officer | 3,138 0.0072% | $22.17 | $69,559 | -14.17% |
Insider Historical Profitability
| Flynn James E | 10 percent owner | 1256542 2.5362% | $7.38 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $160.12M | 15.43 | 7.6M | -7.41% | -$12.82M | <0.01 | |
| The Vanguard Group | $102.76M | 9.9 | 4.88M | +9.82% | +$9.19M | <0.01 | |
| Redmile Group | $95.9M | 9.24 | 4.55M | +21.03% | +$16.66M | 0.98 | |
| JPMorgan Chase | $78.43M | 7.56 | 3.72M | -5.51% | -$4.57M | 0.01 | |
| State Street | $65.79M | 6.34 | 3.12M | +18.68% | +$10.35M | <0.01 |